The living human heart-on-a-chip for drug safety
Many promising drugs are dropped, or pulled from the market, because of dangerous effects on the heart. The tests used today either raise false alarms on safe drugs or miss the real danger, and they still rely on slow, costly and ethically controversial animal studies. EasyCard™ is a micro innervated human heart, that shows whether a drug is safe for the heartbeat in just 30 days, at a fraction of the cost, and with zero animals.
Today's hERG screening over-flags safe drugs and still misses real risks. EasyCard™ reads the whole human heart, nerves included, so you catch the true dangers and stop killing good candidates for the wrong reason.
Terfenadine passed hERG screens yet was pulled from the market. On EasyCard™, its dangerous arrhythmic signature appears only when the heart is innervated. The nerve-heart connection reveals risks that single-cell tests can't see.
+ sensitivityVerapamil blocks hERG but is perfectly safe in patients. EasyCard™ reads it correctly: arrhythmic activity stays at baseline, so good candidates aren't killed for the wrong reason. Fewer false positives, less wasted development.
+ specificitySome rhythm risks only appear when the nervous system is active. Stimulating the on-chip nerves changes the heartbeat in a real, measurable way (+50% beating rate), letting EasyCard™ reveal autonomic risks that until now only live animal studies could catch.
first in vitro04 · How it works
A single, automated run takes your compound from seeding to a risk readout in one month. No animal study, no multi-month CRO cycle.
05 · What we deliver
No half-answers. Every study gives you the clear yes/no verdict and the full picture behind it, so you don't just learn whether there's a heart-rhythm risk, but exactly where it comes from. One engagement, one report, the whole story.
A single study takes your molecule from the go/no-go safety call all the way to the deep dive into why the risk exists. Most tests only tell you if there's a problem. We tell you where it comes from, in the same run, so from the very first month you know whether a molecule is worth pushing forward, what to fix, or what to target to keep its development on track.
Output · clear verdict + full risk profile06 · Who we are
06 · Get in touch